カテゴリ： GlobalData, アメリカ, 企業調査

TESARO Inc (TSRO)：製薬・医療：M&Aディール及び事業提携情報

◆英語タイトル：TESARO Inc (TSRO) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード：DATA904C9878
◆発行会社（調査会社）：GlobalData
◆発行日：2018年11月
◆ページ数：85
◆レポート言語：英語
◆レポート形式：PDF
◆納品方法：Eメール
◆対象地域：アメリカ
◆産業分野：製薬・医療
◆販売価格オプション（消費税別）
Single User（1名様閲覧用）USD250 ⇒換算￥37,000見積依頼/購入/質問フォーム
Site License（同一事業所内共有可）USD500 ⇒換算￥74,000見積依頼/購入/質問フォーム
Enterprisewide License（複数事業所内共有可）USD750 ⇒換算￥111,000見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※本体価格が￥30,000未満のレポートにつきましては、ハンドリングチャージ￥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
※GlobalData社の概要はこちらでご確認いただけます。

このエントリーをはてなブックマークに追加
LINEで送る


【レポートの概要】

Summary
TESARO Inc (TESARO) is an oncology-focused biopharmaceutical company that focuses on developing in-licensed, oncology-related product candidates and discovery of new candidates. It develops products using different approaches, comprising small molecules and immuno-oncology antibodies. The company’s product portfolio includes ZEJULA (niraparib), to treat recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer and VARUBI (rolapitant) for the prevention of chemotherapy induced nausea and vomiting (CINV). TESARO sells its products directly to hospitals and clinics, and to a limited number of specialty distributors and pharmacy providers in the US and to certain wholesale distributors in Europe. TESARO is headquartered in Waltham, Massachusetts, the US.

TESARO Inc (TSRO) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
TESARO Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
TESARO Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
TESARO Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
TESARO Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
TESARO Inc, Medical Devices Deals, 2012 to YTD 2018 10
TESARO Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
TESARO Inc, Pharmaceuticals & Healthcare, Deal Details 13
Partnerships 13
Tesaro Enters into Collaboration Agreement with Genentech 13
Tesaro and Medison Pharma Enter into Distribution Agreement 14
Tesaro Enters into Partnership with Genentech 15
OncoQuest Enters into Agreement with Tesaro 16
Evotec and Tesaro Enter into Agreement 17
Myriad Genetics Enters into Research Agreement with Tesaro and Merck 18
Licensing Agreements 19
TESARO Enters into Research and Licensing Agreement with TeneoBio 19
Millennium Pharma Enters into Licensing Agreement with Tesaro 20
Zai Lab Enters into Licensing Agreement with Tesaro 21
Janssen Biotech Enters into Licensing agreement with Tesaro 22
Tesaro Enters into Licensing Agreement with MD Anderson Cancer Center 23
Jiangsu Hengrui Medicine Enters into Licensing Agreement with Tesaro 24
Tesaro Amends Licensing Agreement With AnaptysBio 25
Tesaro Enters into Licensing Agreement with AstraZeneca 26
Tesaro Enters Into Licensing Agreement With Merck Sharp & Dohme For Cancer Drug 27
Equity Offering 28
Tesaro Raises USD236.3 Million in Public Offering of Shares 28
Tesaro Raises USD433.2 Million in Public Offering of Shares 30
Tesaro Raises USD50 Million in Private Placement of Shares 32
Tesaro Raises up to USD155 Million in Private Placement of Shares 33
Tesaro Raises USD191.5 Million in Public Offering of Shares 35
Tesaro Completes Public Offering Of Shares For US$100.8 Million 37
Tesaro Completes Public Offering Of Common Stock For US$98 Million 38
Tesaro Announces Partial Exercise Of Underwriter’s Option For IPO For US$87 Million 39
Debt Offering 41
Tesaro Raises USD201.3 Million in Public Offering of 3% Notes Due 2021 41
Asset Transactions 43
TerSera Therapeutics to Acquire North American Rights to Varubi from TESARO 43
Acquisition 44
Tesaro May Sell Itself 44
TESARO Inc – Key Competitors 45
TESARO Inc – Key Employees 46
TESARO Inc – Locations And Subsidiaries 47
Head Office 47
Other Locations & Subsidiaries 47
Recent Developments 48
Financial Announcements 48
Nov 01, 2018: TESARO announces third-quarter 2018 operating results 48
Aug 02, 2018: TESARO announces second-quarter 2018 operating results 51
May 03, 2018: TESARO Announces First-Quarter 2018 Operating Results 53
Feb 27, 2018: TESARO Announces Fourth-Quarter and Full-Year 2017 Operating Results 54
Nov 07, 2017: TESARO Announces Third-Quarter 2017 Operating Results 58
Aug 08, 2017: TESARO Announces Second-Quarter 2017 Operating Results 60
May 09, 2017: TESARO Announces First-Quarter 2017 Operating Results 62
Feb 28, 2017: TESARO Announces Fourth-Quarter 2016 Operating Results 64
Government and Public Interest 66
May 08, 2018: Psychological Effects of Ovarian Cancer Often Overlooked But Can Have a Significant Impact on Patients 66
Product News 68
10/25/2017: TESARO Announces U.S. FDA Approval of VARUBI IV for Delayed Nausea and Vomiting Associated With Cancer Chemotherapy 68
02/27/2017: TESARO Receives Positive CHMP Opinion for VARUBY 70
02/23/2017: Tesaro Receives CHMP Positive Opinion for Varuby (rolapitant) 71
01/12/2018: TESARO Announces Updates to the U.S. Prescribing Information for VARUBI (rolapitant) Injectable Emulsion 72
Product Approvals 73
Sep 11, 2017: NHS Scotland Recommends Tesaro’s Varuby (Rolapitant) For Delayed Nausea And Vomiting In Adults Undergoing Highly Emetogenic Chemotherapy 73
Apr 26, 2017: TESARO Announces Approval of VARUBY (Oral Rolapitant Tablets) by European Commission 74
Jan 11, 2017: TESARO Receives Complete Response Letter for Rolapitant IV from U.S. FDA 76
Clinical Trials 77
Nov 28, 2017: TESARO Announces Availability of VARUBI (rolapitant) IV for Delayed Nausea and Vomiting Associated With Cancer Chemotherapy in the United States 77
Sep 11, 2017: TESARO Summarizes TSR-042 Data Presented at 2017 ESMO Annual Meeting 79
Aug 25, 2017: TESARO Presents Poster on TSR-042 at the 2017 European Society for Medical Oncology (ESMO) Annual Meeting 80
Apr 27, 2017: TESARO Initiates Registrational Development Program for Anti-PD-1 Antibody TSR-042 81
Other Significant Developments 82
Jun 03, 2017: TESARO Provides Business and Pipeline Update at ASCO Investor Briefing 82
Appendix 85
Methodology 85
About GlobalData 85
Contact Us 85
Disclaimer 85

List of Tables
TESARO Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
TESARO Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
TESARO Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
TESARO Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
TESARO Inc, Deals By Therapy Area, 2012 to YTD 2018 9
TESARO Inc, Medical Devices Deals, 2012 to YTD 2018 10
TESARO Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Tesaro Enters into Collaboration Agreement with Genentech 13
Tesaro and Medison Pharma Enter into Distribution Agreement 14
Tesaro Enters into Partnership with Genentech 15
OncoQuest Enters into Agreement with Tesaro 16
Evotec and Tesaro Enter into Agreement 17
Myriad Genetics Enters into Research Agreement with Tesaro and Merck 18
TESARO Enters into Research and Licensing Agreement with TeneoBio 19
Millennium Pharma Enters into Licensing Agreement with Tesaro 20
Zai Lab Enters into Licensing Agreement with Tesaro 21
Janssen Biotech Enters into Licensing agreement with Tesaro 22
Tesaro Enters into Licensing Agreement with MD Anderson Cancer Center 23
Jiangsu Hengrui Medicine Enters into Licensing Agreement with Tesaro 24
Tesaro Amends Licensing Agreement With AnaptysBio 25
Tesaro Enters into Licensing Agreement with AstraZeneca 26
Tesaro Enters Into Licensing Agreement With Merck Sharp & Dohme For Cancer Drug 27
Tesaro Raises USD236.3 Million in Public Offering of Shares 28
Tesaro Raises USD433.2 Million in Public Offering of Shares 30
Tesaro Raises USD50 Million in Private Placement of Shares 32
Tesaro Raises up to USD155 Million in Private Placement of Shares 33
Tesaro Raises USD191.5 Million in Public Offering of Shares 35
Tesaro Completes Public Offering Of Shares For US$100.8 Million 37
Tesaro Completes Public Offering Of Common Stock For US$98 Million 38
Tesaro Announces Partial Exercise Of Underwriter’s Option For IPO For US$87 Million 39
Tesaro Raises USD201.3 Million in Public Offering of 3% Notes Due 2021 41
TerSera Therapeutics to Acquire North American Rights to Varubi from TESARO 43
Tesaro May Sell Itself 44
TESARO Inc, Key Competitors 45
TESARO Inc, Key Employees 46
TESARO Inc, Subsidiaries 47

List of Figures
TESARO Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
TESARO Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
TESARO Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
TESARO Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
TESARO Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
TESARO Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
TESARO Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
TESARO Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
TESARO Inc, Medical Devices Deals, 2012 to YTD 2018 10

★海外企業調査レポート[TESARO Inc (TSRO)：製薬・医療：M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら
■おすすめ企業レポート■
  • Interface Biologics Inc：医療機器：M&Aディール及び事業提携情報
    Summary Interface Biologics Inc (IBI) is a medical device company that develops transformative biomedical polymer technologies. The company offers anti-thrombogenic and combination drug delivery devices. Its anti-thrombogenic additives reduce thrombosis in blood contacting medical devices and polyme …
  • EFG International AG：企業の戦略・SWOT・財務分析
    EFG International AG - Strategy, SWOT and Corporate Finance Report Summary EFG International AG - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • Tata Motors Limited：企業の戦略・SWOT・財務分析
    Tata Motors Limited - Strategy, SWOT and Corporate Finance Report Summary Tata Motors Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • Wirecard AG：企業の戦略・SWOT・財務分析
    Wirecard AG - Strategy, SWOT and Corporate Finance Report Summary Wirecard AG - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate act …
  • Fastenal Co：戦略・SWOT・企業財務分析
    Fastenal Co - Strategy, SWOT and Corporate Finance Report Summary Fastenal Co - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate act …
  • Impala Platinum Holdings Ltd：企業の戦略・SWOT・財務情報
    Impala Platinum Holdings Ltd - Strategy, SWOT and Corporate Finance Report Summary Impala Platinum Holdings Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and s …
  • R-Biopharm AG：医療機器：M&Aディール及び事業提携情報
    Summary R-Biopharm AG (R-Biopharm), a subsidiary of Rohm Gmbh & Co KG, is a developer of test solutions for clinical diagnostics and food and feed analysis. The company offers test systems in the areas of infectological stool diagnostics, serological infection and allergy diagnostics for clinical di …
  • Avraham Pharmaceuticals Ltd：製薬・医療：M&Aディール及び事業提携情報
    Summary Avraham Pharmaceuticals Ltd (Avraham Pharmaceuticals) is a pharmaceutical company that develops novel products for treatment and prevention of neurodegenerative disorders. The company offers a product, Ladostigil. It offers product in the therapeutic area of mild cognitive impairment. Avraha …
  • Icahn Enterprises LP：企業のM&A・事業提携・投資動向
    Icahn Enterprises LP - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Icahn Enterprises LP Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A …
  • CorEnergy Infrastructure Trust Inc (CORR)：企業の財務・戦略的SWOT分析
    CorEnergy Infrastructure Trust Inc (CORR) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strength …
  • Max Delbruck Center for Molecular Medicine：製薬・医療：M&Aディール及び事業提携情報
    Summary Max Delbruck Center for Molecular Medicine (MDC) is a biomedical research center that offers translating discoveries from molecular research into applications. The company’s research area services offer for cancer research, cardiovascular and metabolic disease, diseases of the nervous system …
  • PolyPid Ltd (POLY)：製薬・医療：M&Aディール及び事業提携情報
    Summary PolyPid Ltd (PolyPid) is a pharmaceutical company that develops manufactures and commercializes therapies for the treatment of various medical conditions including infection, pain, inflammation and cancer. The company’s pipeline product candidates include D-Plex100, an antibiotic drug reserv …
  • Cara Therapeutics Inc (CARA)：製薬・医療：M&Aディール及び事業提携情報
    Summary Cara Therapeutics Inc (Cara Therapeutics) is a biotechnology company that develops and commercializes chemical entities for acutepain, chronic pain and pruritus. The company offers kappa opioid receptor agonists in the therapeutic areas of acute pain, chronic pain, neuropathic pain and pruri …
  • Surge Energy Inc (SGY)：石油・ガス：M&Aディール及び事業提携情報
    Summary Surge Energy Inc (Surge) is an oil and gas company that offers acquisitions, exploration and production of crude oil and natural gas reserves. The company provides risk management and risk development drilling services. Its oil and natural gas producing properties include Shaunavon and Dodsl …
  • Volta River Authority：企業の戦略的SWOT分析
    Volta River Authority - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and …
  • Holding Slovenske elektrarne doo：企業の戦略的SWOT分析
    Holding Slovenske elektrarne doo - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major pr …
  • Trillion Energy International Inc (PKPL)：企業の財務・戦略的SWOT分析
    Summary Trillion Energy International Inc (Trillion Energy) formerly Park Place Energy Inc, is an oil and gas company that offers exploration and development of oil and natural gas. The company offers various oil and gas services such as drilling, exploration, development, production, distribution a …
  • Landec Corp (LNDC)：企業の財務・戦略的SWOT分析
    Summary Landec Corp (Landec) is a diversified health solution service provider. The company offers offers food and biomaterial solutions. It develops and markets innovative and proprietary based products for healthy living. The company offers various technologies such as application development and …
  • Ardian Holding SAS：企業の戦略的SWOT分析
    Ardian Holding SAS - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and ser …
  • iMedX Inc-医療機器分野：企業M&A・提携分析
    Summary iMedX Inc (iMedX) is a provider of medical document management and health information solutions. The company offers transcription services and coding services. It provides iMedX Express web based platforms and iMedX Mobile with DocAssist applications. iMedX’s transcription services comprise …

◆H&Iグローバルリサーチ株式会社のお客様（例）◆